Rapid Micro Biosystems, Inc. (RPID) company profile

The company develops and commercializes automated microbial quality control solutions for pharmaceutical and biopharmaceutical manufacturing. Its core offering is the Growth Direct platform, an automated system that detects and enumerates microbial contamination in manufacturing environments, water systems, raw materials, and finished sterile products. The platform integrates robotic handling, optical imaging, and vision algorithms to replace manual growth-based testing methods. The company also supplies proprietary consumable plates designed for specific testing applications, laboratory information management system connectivity software, and consultative validation and maintenance services. Its customers include global pharmaceutical companies and manufacturers of advanced therapeutics such as biologics, vaccines, sterile injectables, and cell and gene therapies.

The company operates internationally, serving customers across approximately 107 sites in 18 countries. It maintains direct sales forces in North America, Europe, and the Asia-Pacific region, complemented by third-party distribution partners, and has placed 190 systems globally. The provided text does not state the location of the company's headquarters.

Summary of the business section of Rapid Micro Biosystems's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 171 full-time employees across the globe, of which 34 were engaged in sales and marketing, 34 in research and development, 74 in manufacturing and service, and 29 in general and administrative.”